IAVI and its partners are advancing a diverse porfolio of select preventive HIV vaccine candidates.
IAVI details its organizational strategic vision for the period 2011-2015 made.
Engage with IAVI on your social media networks.
IAVI partners with more than 50 academic, biotechnology, pharmaceutical and governmental institutions to develop AIDS vaccines, and to advocate for the HIV-prevention field.
IAVI is working with partners to ensure that once a preventive AIDS vaccine is developed, it will be available to those who need it most.
As researchers make significantprogress toward the development ofan AIDS vaccine, new modeling datahighlights its potentially striking impact.
IAVI and its partners have conducted dozens of studies to advance the development of safe and effective AIDS vaccines. Navigate the studies database for details of our current and ongoing clinical, observational, policy, and social research.
New studies show the promise of alternate serotype adenovirus vector-based HIV vaccine candidates, but also raise questions about their ability to overcome pre-existing immunity issues.